<DOC>
	<DOC>NCT01878123</DOC>
	<brief_summary>This is a Phase 1, single-dose, placebo-controlled, dose-escalation,multi-center, first time in human study of AMP-110 in adult subjects with rheumatoid arthritis.</brief_summary>
	<brief_title>Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Must be able to provide written informed consent Body mass index 18.5 to 35.0 kg/m2 Diagnosis of Rheumatoid Arthritis according to 1987 revised American College of Rheumatology (ACR) criteria Global Functional Class I, II, or III according to ACR 1991 revised criteria Stable use of &gt;/= 1 Disease Modifying Antirheumatic Drugs (DMARD) for &gt;/= 4 weeks prior to Day 0, including: 1. Methotrexate (MTX) 7.5 25 mg/week 2. Hydroxychloroquine (HCQ) &lt;/= 400 mg/day 3. Sulfasalazine (SSZ) 1,000 3,000 mg/day 4. Leflunomide 5 20 mg/day 5. Azathioprine 150 mg/day or 2 mg/kg/day 6. Combinations of MTX, HCQ, and/or SSZ allowed Prior to Day 0, use of 1. Abatacept 2. Rituximab within 6 months 3. Infliximab, Adalimumab, Certolizumab, Tocilizumab, Cyclosporine, or Mycophenolate mofetil within 2 months 4. Etanercept or Anakinra within 28 days 5. Immunoglobulin or blood products within 28 days Evidence of any active or recent infection including ongoing, chronic infectious disease such as chronic renal infection or chronic chest infection with bronchiectasis or sinusitis History of systemic autoimmune disease other than Rheumatoid Arthritis History of allergic reactions to other protein therapeutics such as monoclonal antibodies or fusion proteins History of anaphylaxis or allergic diathesis Clinically significant cardiac disease, including: unstable angina; myocardial infarction within 6 months; congestive heart failure; arrhythmia requiring active therapy, with the exception of clinically insignificant extrasystoles, or minor conduction abnormalities; and history of clinically significant abnormality on electrocardiogram Evidence of active or latent tuberculosis Vaccination wtih live attenuated viruses within the 2 weeks prior to Day 0 Evidence of infection with hepatitis B virus, hepatitis C virus, human immunodeficiency virus 1 or 2, or active infection with hepatitis A Pregnant or breastfeeding women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Joint Diseases</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Rheumatic Diseases</keyword>
	<keyword>Connective Tissue Diseases</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Antirheumatic agents</keyword>
</DOC>